These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 6990871)

  • 1. Antimalarial agents. Chloroquine, hydroxychloroquine, and quinacrine.
    Tanenbaum L; Tuffanelli DL
    Arch Dermatol; 1980 May; 116(5):587-91. PubMed ID: 6990871
    [No Abstract]   [Full Text] [Related]  

  • 2. Antimalarials.
    Koranda FC
    J Am Acad Dermatol; 1981 Jun; 4(6):650-5. PubMed ID: 6165744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases.
    Al-Bari MA
    J Antimicrob Chemother; 2015; 70(6):1608-21. PubMed ID: 25693996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are the Current Recommendations for Chloroquine and Hydroxychloroquine Screening Appropriate?
    Schwartzman S; Samson CM
    Rheum Dis Clin North Am; 2019 Aug; 45(3):359-367. PubMed ID: 31277749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical properties of anti-inflammatory drugs. VI. The effects of chloroquine (resochin), mepacrine (quinacrine) and some of their potential metabolites on cartilage metabolism and oxidative phosphorylation.
    Whitehouse MW; Boström H
    Biochem Pharmacol; 1965 Aug; 14(8):1173-84. PubMed ID: 4221789
    [No Abstract]   [Full Text] [Related]  

  • 6. [Eye toxicity of antimalarial agents].
    Graña Gil J; Cabana Vázquez M; Vázquez González A; Sánchez Meizoso MO
    An Med Interna; 2002 Apr; 19(4):189-91. PubMed ID: 12090061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimalarial therapy for lupus erythematosus: an apparent advantage of quinacrine.
    Zuehlke RL; Lillis PJ; Tice A
    Int J Dermatol; 1981; 20(1):57-61. PubMed ID: 7203769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocular toxicity of antimalarial drugs. Long-term follow-up.
    Carr RE; Henkind P; Rothfield N; Siegel IM
    Am J Ophthalmol; 1968 Oct; 66(4):738-44. PubMed ID: 5729592
    [No Abstract]   [Full Text] [Related]  

  • 9. [Complications with synthetic antimalarials].
    Huriez C; Desmons F; Gautier G; Dhellemmes
    Lille Med; 1969 Oct; 14(8):851-64. PubMed ID: 4251585
    [No Abstract]   [Full Text] [Related]  

  • 10. Biochemical properties of anti-inflammatory drugs. VII. Inhibition of proteolytic enzymes in connective tissue by chloroquine (resochin) and related antimalarial antirheumatic drugs.
    Cowey FK; Whitehouse MW
    Biochem Pharmacol; 1966 Aug; 15(8):1071-84. PubMed ID: 4292639
    [No Abstract]   [Full Text] [Related]  

  • 11. Antimalarial therapy in SLE.
    Lanham JG; Hughes GR
    Clin Rheum Dis; 1982 Apr; 8(1):279-98. PubMed ID: 6749400
    [No Abstract]   [Full Text] [Related]  

  • 12. Antimalarial drugs in the treatment of rheumatological diseases.
    Rynes RI
    Br J Rheumatol; 1997 Jul; 36(7):799-805. PubMed ID: 9255117
    [No Abstract]   [Full Text] [Related]  

  • 13. Biochemical effects of chloroquine therapy in porphyria cutanea tarda.
    Vogler WR; Galambos JT; Olansky S
    Am J Med; 1970 Sep; 49(3):316-21. PubMed ID: 5455563
    [No Abstract]   [Full Text] [Related]  

  • 14. Chloroquine.
    Copeman PW
    Trans St Johns Hosp Dermatol Soc; 1967; 53(1):24-45. PubMed ID: 4865867
    [No Abstract]   [Full Text] [Related]  

  • 15. Antimalarial Quinacrine and Chloroquine Lose Their Activity by Decreasing Cationic Amphiphilic Structure with a Slight Decrease in pH.
    Kitagawa T; Matsumoto A; Terashima I; Uesono Y
    J Med Chem; 2021 Apr; 64(7):3885-3896. PubMed ID: 33775096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus.
    Feldmann R; Salomon D; Saurat JH
    Dermatology; 1994; 189(4):425-7. PubMed ID: 7873836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of mepacrine, chloroquine and hydroxychloroquine on superoxide anion generation, phospholipid methylation and arachidonic acid release by human blood monocytes.
    Hurst NP; French JK; Bell AL; Nuki G; O'Donnell ML; Betts WH; Cleland LG
    Biochem Pharmacol; 1986 Sep; 35(18):3083-9. PubMed ID: 3019354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Supervision of the eyes during prolonged treatment with synthetic antimalarial drugs. Results in 237 patients followed up for 4 years on the average].
    Bertrand JJ; Debeyre N; Kahn MF; Ryckewaert A
    Presse Med (1893); 1968 Nov; 76(45):2139-42. PubMed ID: 5720115
    [No Abstract]   [Full Text] [Related]  

  • 19. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds.
    Macfarlane DE; Manzel L
    J Immunol; 1998 Feb; 160(3):1122-31. PubMed ID: 9570525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature.
    Osadchy A; Ratnapalan T; Koren G
    J Rheumatol; 2011 Dec; 38(12):2504-8. PubMed ID: 22002012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.